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ABSTRACT
Introduction: MiR-3099 was reported to play a role in neuronal cell differentiation/function in the brain during late 
embryonic and early neonatal development. To further explore its potential regulatory effects on embryonic brain 
development, this study aims to construct and validate an expression vector of miR-3099 for future gain-of-function 
and loss-of-function studies.  Methods: pCAG-eGFP vector was modified to include IRES2 and miR-3099 with 150bp 
upstream and downstream genomic sequences. The newly constructed vector, pCAG-miR-3099-IRES2-eGFP, con-
sists of CAG promoter. The in vitro expression level of miR-3099 was measured using stem-loop RT-qPCR after it 
was transfected into 293FT cell. Later, the vector was electroporated into the embryonic brain at E15.5. Three days 
later, the E18.5 embryonic brain was harvested and cryopreserved. Immunohistochemistry was performed by using 
antibody against eGFP to validate the in utero expression of the transgene in the neocortex of the brain. Results: Our 
finding showed that, the expression level of miR-3099 was significantly upregulated (p<0.001) in cells transfected 
with miR-3099 vector as compared to both negative and empty plasmid control groups. In addition, the expression 
of eGFP was noted in the brain section indicating that the vectors with or without miR-3099 transgene were success-
fully transfected into and expressed in the neocortex upon electroporation. Conclusion: The bicistronic expression 
vector of miR-3099 which was driven by the CAG promoter was successfully constructed, validated and sufficiently 
delivered to brain cells via the in utero electroporation approach.  The regulatory roles of miR-3099 in embryonic 
brain development can be manipulated using similar approach.
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INTRODUCTION
MicroRNAs (miRNAs) are a small non-coding RNAs 
that plays a major role in mediating post-transcriptional 
regulation of gene expression. In 2011, miR-3099 was 
discovered and found to be expressed as early as in 
blastocyst stage, which the expression was maintained 
until E11.5 in the developing mouse brain (1). The 
expression of miR-3099 was further restricted to the 
cortical plate of the developing mouse brain between 
E13.5 and E17.5, coinciding with the time that majority 
of the cells are committed to neuronal cell lineage (1). 
Moreover, the miR-3099 was also found to be highly 
expressed in differentiating P19 cell, with approximately 
2-fold upregulation as compared to proliferating P19 
cell (1). In a different study, the expression of miR-3099 
was upregulated by 2-3 folds in 46C mouse embryonic 
stem (mES) cell upon neural induction (2). The 
expression profiles revealed an interesting result when 
embryo-wide expression of miR-3099 in mid-gestation 
embryos became restricted to the central nervous system 
(CNS) suggesting its potential role in regulating mouse 
embryogenesis as well as neuronal cell development 
and function.
Genetic modification is one of the common approaches 
to elucidate the functional role of a gene of interest in 
the biological system. The modification either through 
the ‘gain-of-function’ or ‘loss-of-function’ approach 
requires a vector system that is able to drive and report 
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the expression of the transgene or its inhibitor efficiently 
in tissues of interest. The common vector delivery 
systems used are via viruses or liposomes. The choice of 
delivery methods depends mainly on the purpose of the 
study, the needed duration of transgene expression, the 
type of cells used and whether the transgene expression 
is regulatable or toxic to the host cell (3–6). In addition, 
electroporation has been increasingly used to deliver 
transgenes directly into the host after the permeability 
of the cell membrane was compromised by electrical 
pulses creating small pores that allow nucleic acids to 
pass through (7–9). The technique could also be used 
to deliver transgenes into the regions of interest of the 
developing mouse brain of embryos using in utero or 
ex utero surgeries making the approach more directed 
and creating an in vivo transgenic condition to assess 
the role of transgenes in a more targeted format over 
a specific developmental window (6–8; 10–12). The 
approach allows the temporary creation of in utero 
transgenic model and enables the study of genes that are 
developmentally lethal to the host when inactivated in a 
knockout animal model. The simplicity of this technique 
provides a rapid investigation and direct examination of 
the function of delivered genes (7-8; 10-11). 
The construction and design of the recombinant plasmid 
plays a crucial role to successfully establish an in utero 
expression system. Several features that need to be 
considered when constructing the plasmid, namely, the 
promoter or enhancer region, internal ribosomal entry 
site (IRES), Cre-LoxP system, tetracycline responsible 
element and epitope-tag, selection markers and 
reporter genes (e.g. red or green fluorescent proteins) 
(13). Although this system is very useful to study early 
development of CNS, the normal course of development 
cannot be maintained for a long time under in vitro 
culture conditions (13). In in utero studies, the transgene 
expression in neurones has been successfully maintained 
up to 30-day postnatally in a number of cases (3). The 
level and duration of transgene expression, however, 
are dependent on the type of promoter used to drive 
the expression in the tissues of interests. This study 
aimed to construct and validate a bicistronic vector 
driven by a CAG promoter, consists of a IRES2 site, 
new multiple cloning sites, miR-3099 pre-miRNA and 
enhanced GFP as reporter gene. Thus, the expression 
vector for miR-3099 could be used to study molecular 
and cellular regulatory roles of the miRNA via in utero 
electroporation approach in the developing neocortex 
of the mouse embryo. 
METHODOLOGY
Experimental Animal
All the animal procedures were performed according 
to Animal Care and Use Committee approval (UPM/
FPSK/PADS/BR-UUH/00469). The C57BL/6J strain 
mice were used in this study. Breeding colonies or the 
mouse model were obtained from the Medical Genetics 
Laboratory (MGL), Universiti Putra Malaysia (UPM). 
Mice were maintained in a 12:12 hour schedule of 
light-dark cycle under constant temperature and relative 
humidity condition. The ventilation was kept running for 
24 hours, allowing a good air circulation in the room. 
The animals were allowed free access to the standard 
pellet and sterile water. Corn cobs were used as animal 
bedding and the bedding was changed every week. The 
stud male mice aged 4 months old  (14) were caged 
individually with female mice (average age of 6 weeks 
old) for approximately 12 hours. A copulation plug was 
checked in the following morning to verify successful 
mating. 
 
Plasmid Preparation, Cloning and Screening
At least 10 µg of DNA was digested with 100 units 
of enzyme in 100 µl of total reaction volume. The 
following enzymes were used in either double-
digestion or sequential single digestion reactions using 
the appropriate buffer system providing 100% activity 
according to the manufacturer’s instructions: (1) BglII 
(NEB, UK) and EcoRI-HF (NEB, UK) for eGFP amplicon 
and pCAG-eGFP, (2) XhoI (NEB, UK) and EcoRI-HF 
(NEB, UK) for IRES2 amplicon and pCAG-eGFP-XhoI, (3) 
XmaI (NEB, UK) and EcoRI-HF (NEB, UK) for miR-3099 
amplicon and pCAG-IRES2-eGFP. The 1X CutSmart 
buffer (NEB, UK) was used in the combination of either 
XhoI or XmaI with EcoRI-HF whereas 1X NEBuffer 
3.1 (NEB, UK) was used for BglII. All digestions were 
performed by incubating the reactions at 37oC for 2 
hours followed by enzyme inactivation for 20 minutes 
at 65oC. All digested plasmids was treated with 10 units 
of calf intestinal alkaline phosphatase (NEB, UK) in 1X 
CutSmart buffer for 1 hour to dephosphorylate the 5’ 
end to prevent re-ligation of linearized vectors with the 
cut DNA. All digested plasmids and amplicons were 
purified using High Pure PCR Product Purification Kit 
(Roche Diagnostic, USA) prior to the ligation step.  
All ligation reactions were carried out using 400 units 
of T4 DNA ligase (NEB, UK) in 1X T4 DNA ligase 
buffer (NEB, UK). In brief, 100 ng of purified and 
dephosphorylated plasmid was used to ligate with the 
purified DNA at the ratio of 1 to 5. All ligation reactions 
were incubated at 16°C for overnight followed by an 
inactivation step at 65°C for 10 minutes. A total of 
2.5 µl of ligated mixture was incubated with 50 µl of 
JM109 competent cells (Promega, USA) on ice for 30 
minutes. After that, the mixture was heat-shocked for 45 
seconds at 42oC in a water bath. The transformant was 
immediately incubated on ice for 2 minutes and was 
propagated in 450 µl of SOC media (Invitrogen, USA) at 
37oC for 1 hour with shaking (420 rpm). Subsequently, 
200 µl of transformant was spread on LB agar (BD Difco, 
USA) containing 100 µg ml-1 ampicillin and incubated 
at 37oC for 18 hours. Colonies of bacterial were picked, 
transferred into LB broth (BD Difco, USA) containing 
100 µg ml-1 ampicillin and cultured overnight in an 
incubator shaker (420 rpm) at 37oC. 
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The plasmids were extracted and purified using 
QIAGEN Plasmid Mini Kit (Qiagen, USA) according 
to manufacturer’s instructions. Each of the purified 
transformant plasmid was further validated either using 
polymerase chain reaction (PCR) or restriction enzyme 
analysis. Each PCR reaction was prepared in 20 µl 
containing 30 ng of genomic/plasmid DNA, 0.5 µM of 
each forward and reverse primer and 1X LC480® Probe 
Master (Roche Diagnostic, USA). The PCR reaction 
was cycled in Eppendorf Mastercycler® Gradient PCR 
machine (Eppendorf, USA) with an initial denaturation 
step at 94°C for 10 minutes followed by 40 cycles of 
94°C for 10 seconds, 58-60°C for 30 seconds and 72°C 
for 10 seconds with an additional elongation step at 
72°C for 5 minutes. Qualitative analysis was performed 
on electrophoresed DNA bands in ethidium bromide 
stained 1-2% (w/v) agarose gel. All primers used in 
this study were designed using OligoCalc programme 
(http://basic.northwestern.edu/biotools/OligoCalc.
html) (15). Positive clones were further confirmed 
by direct sequencing and cultivated for large-scale 
preparation using QIAGEN Plasmid Mega Kit (Qiagen, 
USA) according to manufacturer’s instructions prior to 
downstream applications.
DNA Sequencing
The positive transformant plasmids were sequenced to 
confirm or validate the clones. The Sanger sequencing 
was performed by First BASE Laboratories Sdn Bhd. 
Generated sequences were aligned to the reference 
sequences and analysed using DNA Baser v3.5.4 software 
(16) and National Center of Biotechnology Information 
(NCBI) database – nucleotide BLAST (https://blast.ncbi.
nlm.nih.gov) to determine sequence specificity and any 
potential PCR-induced mutations.
Cell Culture and Transfection
The 293FT cell was maintained in DMEM (Gibco, USA) 
supplemented with 2 mM of L-glutamine (Gibco, USA), 
100 U ml-1 of Penicillin/Streptomycin (Gibco, USA) and 
10% (v/v) of foetal bovine serum (FBS) and cultivated in 
5% of CO2 level incubator at 37oC. A total of 5 µg of 
plasmid was transfected into 1.0 x 106 of 293FT cells 
in suspension using Lipofectamine™ 3000 (Invitrogen, 
US) transfection reagent according to manufacturer’s 
instruction. After 48 hours of transfection, the expression 
of eGFP was detected using IX5 Inverted Fluorescent 
microscope (Olympus, USA).       
Stem-loop Reverse Transcriptase-Quantitative 
Polymerase Chain Reaction
A total RNA was extracted using TRIzol™ reagent 
(Invitrogen, USA) and all the procedures were 
performed according to manufacturer’s protocol. 
A total of 1.5 µg of small RNA enriched total RNA 
was synthesised by using SuperScript™ IV Reverse 
Transcriptase kit with additional of 0.1 µM of stem-
loop primer (5’-GTTGGCTCT GGTAGGATG CCGCTC 
TCA GGGCATCCT ACCAGAGCCA AACTCCCCA-3’) 
according to a published protocol (1). 
Prior to Real-Time-quantitative PCR (qPCR), pre-PCR 
of miR-3099 was performed in 20 µl of total reaction 
consisting of 1X LC480 Probes Master, 0.5 µM of 
each forward (5’-CGCGTAGGC TAGAGAGAG GT-
3’) and universal reverse primer (5’-GTAGGATGC 
CGCTCTCAG G-3’) and 0.3X of synthesised cDNA. 
The pre-PCR and qPCR were essentially carried out 
according to a previously published protocol (1). All 
reactions were prepared in a 96-well plate format and 
qPCR was performed using LightCycler 480 Instrument 
II. The amplification signals were acquired during the 
elongation step and recorded by using LightCycler® 480 
Software version 1.5. The cycle threshold or crossing 
point (Cp) from each signal was calculated based on the 
Second Derivative Maximum method (17) and the relative 
quantification by standard curve approach described 
previously (18) was adopted for data comparison. The 
U6 gene was used to normalise the quantitative analysis. 
The UPL Probe #U6 (F-CATGGCCCC-Q) was used to 
quantitate the expression of U6 gene. Primers used to 
amplify U6 gene were 5’-CGCTTCGGC AGCACATAT 
A-3’ (forward) and 5’-AAATATGGA ACGCTTCAC 
GAAT-3’ (reverse). 
In Utero Electroporation
A pregnant mouse with E15.5 embryos was anaesthetised 
with an induction dose of 4% (v/v) isoflurane gas 
followed by 1.5% (v/v) maintenance dose during surgery 
(Figure 1a-b). The anaesthetised mouse was placed on 
a heating pad with its ventral side up. The hair of the 
abdomen was shaved and sterilised with alternating 
scrubs of betadine and 70% ethanol for three times. A 
small incision was made at the abdomen midline and 
the uterine horns were carefully pulled out onto 37°C 
pre-warmed 0.9% sodium chloride (NaCl) solution-
moistened cotton gauze, which was placed around the 
incision (Figure 1c-d).  
The embryos were gently squeezed between forefinger 
and the thumb to push the embryo closer to the uterine 
wall. A total of 10 µg (in 1 µl) of plasmid mixed with 
0.1% fast green solution was then injected into one side 
of lateral ventricles of an embryo with a pulled glass 
micropipetter made from a microcapillary tube (Figure 
1e-g). The injection was repeated on all the embryos and 
the site of injection was placed between the tweezers-
type platinum electrodes which were 5 mm in diameter 
at the tip (CUY650-5; NEPAGene Co., LTD, Japan). The 
positive electrode was placed at the side of the brain in 
line with the direction of electroporation whereas the 
negative electrode was placed at the opposite side away 
from the site of electroporation (Figure 1h). NEPA21 
Electro-Kinetic Transfection System (NEPAGene Co., 
LTD, Japan) was used to produce electric pulses on the 
across the tissues between electrodes. The parameters 
set on E15.5 were: 30V was applied five times with 50 
ms of pulsing duration and 450 ms interval between 
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Figure 1: Mouse surgery, microinjection and in utero electroporation
(a) A pregnant mouse was anaesthetized in a chamber before (b) it is placed under isoflurane maintenance via a gas 
nozzle. Ophthalmic oilment was applied to prevent desiccation of cornea. (c) The animal is placed on an absorbent 
pad covering the heated pad. The abdominal wall is then shaved with surgical clippers. Incision is then made at the 
abdomen midline. (d) Uterine horns with the embryos are made visible and gently pulled out onto pre-warmed and 
moistened cotton gauze. (e-f) The head of the embryo is held in between forefinger and the thumb. Plasmid mixed 
with fast green dye is injected into the ventricle of the embryo. (g) Successful intraventricular injection is confirmed 
with the fast-green dye visible throughout the lateral ventricle. (h) Electrodes are placed at the sides of the head for 
electroporation. (i) After electroporation, embryos are gently returned into the abdominal cavity before the (i) perito-
neum and (j) abdominal skin were suture using polysyn and nylon sutures, respectively.  
pulses. The electroporation was repeated on all the 
embryos injected with the plasmid.
Once the procedure was completed, the uterine horns 
were returned into the abdominal cavity filled with 0.9% 
NaCl (Figure 1i). The abdominal wall and skin were 
closed with polysyn and nylon sutures, respectively 
(Figure 1j-k). Alternate scrubs of betadine and 70% 
ethanol were applied three times on the suture before 
applying the Fucidin to prevent infection after surgery. 
A total of 0.25 mg ml-1 non-steroidal anti-inflammatory 
analgesia, meloxicam, was given via intraperitoneal 
injection. After the surgery, the pregnant mouse was 
removed from isoflurane anaesthesia and placed on a 
heated recovery cage until it regained movement before 
returning it to the maintenance cage. The animals were 
observed for signs of distress or pain for the following 
three days.        
Tissue Preparation
E18.5 mouse embryos were dissected from the pregnant 
mouse and the whole brain was harvested and fixed 
overnight with 4% paraformaldehyde (PFA) in 1X 
phosphate-buffered saline (PBS) at 4oC. After washing 
three times with 1X PBS for 10 minutes each time, 
the samples were equilibrated in 30% sucrose in 1X 
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phosphate-buffered saline (PBS) at 4oC. After washing 
three times with 1X PBS for 10 minutes each time, 
the samples were equilibrated in 30% sucrose in 1X 
PBS. Then, the samples were embedded in Optimal 
Cutting Temperature (OCT) compound (ThermoFisher 
Scientific, USA), cryopreserved and stored at -80°C. The 
brains were sectioned coronally at 30 µm thickness by 
using cryostat (CM1900, Leica, USA) and mounted onto 
Superfrost™ Plus slides (ThermoFisher Scientific, USA). 
Immunohistochemistry
The brain section was permeabilised with 1X PBS 
containing 0.1% (v/v) Triton X-100 for 3 times (10 
minutes each) followed by blocking with 1X PBS 
containing 0.1% (v/v) Triton X-100, 1% (w/v) Bovine 
Serum Albumin (BSA) and 10% (v/v) heat inactivation 
foetal bovine serum for 1 hour at room temperature. Then, 
the brain section was incubated with anti-GFP [mouse 
monoclonal (MAB3580), Merck, Germany] with dilution 
factor 1:500. The sections were incubated in humidified 
chamber for overnight at 4oC. Then, the sections were 
washed three times with 1X PBS (10 minutes each) 
and incubated with the secondary antibody (Goat anti-
mouse Alexa Fluor 488, ThermoFisher Scientific, USA) 
with dilution factor 1:1000 in humidified chamber for 
2 hours at room temperature. The sections were rinsed 
three times with 1X PBS, mounted with ProLong™ Gold 
Antifade Mountant reagent with DAPI (ThermoFisher 
Scientific, USA) and covered with cover slip prior 
to observe under confocal microscope (FluoView 
FV1200, Olympus, USA).   
RESULTS
In this study, pCAG-eGFP backbone plasmid was a 
gift from NEPAGene Co., LTD, Japan. The plasmid 
was previously validated for in utero electroporation 
analysis (19). However, the plasmid is still lacking a few 
features that are relevant for the expression of a small 
RNA such as miR-3099. It was modified to include 
multiple cloning sites, IRES2 and the microRNA of 
interest, miR-3099. First, eGFP from pCAG-eGFP vector 
was PCR amplified using a pair of primers containing 
the original EcoRI restriction enzyme site and new XhoI 
sites (5’- CCATCACTT TGGCAAAGC ACGTGAATTC 
TGTTTCTCGAG ACACCATG-3’) upstream and BglII 
site (5’-CGCGCGTGA GGAAGAGATCT TGCAGCTCG 
GTGACCCGC TCGAT-3’) downstream of eGFP (size 
947 bp). The original eGFP CDS was excised from the 
vector using BglII (NEB, UK) and EcoRI-HF (NEB, UK) 
enzymes and directionally replaced with the digested 
PCR-amplified eGFP (using similar restriction enzymes) 
containing the additional XhoI site upstream of the 
CDS. This plasmid is termed pCAG-eGFP-XhoI (Figure 
2a-i). Next, IRES2 was PCR amplified from pEF1α-IRES-
AcGFP1 plasmid (Clontech, USA) using forward primer 
(5’-CCGGACTCA GATCTCGAG CTCAA-3’) and reverse 
primer containing XhoI restriction site (5’-CCCTTGCTC 
ACTCGAGTT GTGG-3’). The amplicon product of IRES2 
was 667 bp and the first 66 bp consists of restriction site 
for EcoRI and XmaI. The newly generated pCAG-eGFP-
XhoI was then digested with XhoI (NEB, UK) and EcoRI-
HF. Then, the PCR-amplified IRES2 was digested with the 
same restriction enzymes and directionally cloned into 
the cut pCAG-eGFP-XhoI to generate the new pCAG-
IRES2-eGFP (Figure 2a-ii) containing the EcoRI and 
XmaI sites upstream of IRES2. Finally, miR-3099 with 
150 bp upstream and downstream genomic sequences 
were amplified from mouse gDNA using primers 
containing restriction sites for EcoRI (5’-CTTGTGGTG 
CTTCGAATTC CTGTGCT-3’) and XmaI (5’-CTCATGCT 
CCCGGGTTAT CAGT-3’). PCR-amplified miR-3099 
± 150 bp (size 389 bp) was digested with EcoRI and 
XmaI and directionally cloned into pCAG-IRES2-eGFP 
to produce the final expression vector for miR-3099, 
pCAG-miR-3099-IRES2-eGFP (Figure 2a-iii). All clones 
were either screened by PCR (pCAG-eGFP-XhoI and 
pCAG-IRES2-eGFP) or digested with restriction enzymes 
(pCAG-miR-3099-IRES2-eGFP) (Figure 2b). Positive 
clones were confirmed with direct Sanger sequencing 
method and no mutations were indicated in all the 
stages of vector construction (Figure 2c). 
The validated pCAG-miR-3099-IRES2-eGFP vector was 
transfected into 239FT cells to determine the functionality 
of the expression vector. A mock control and 293FT 
cells transfected with pCAG-IRES2-eGFP were used as 
negative and positive controls, respectively. After 48-
hour post-transfection, eGFP positive cells were seen in 
both pCAG-miR-3099-IRES2-eGFP and pCAG-IRES2-
eGFP groups but not in the mock control group (Figure 
3). The observation confirmed that the modified vectors 
were both functional as indicated by the presence of 
eGFP reporter protein. The expression of miR-3099, 
however, must be validated using stem-loop RT-qPCR 
method which is specific to the mature form of miR-
3099. The analysis showed that the expression level 
of miR-3099 was significantly upregulated (p<0.001) 
in pCAG-miR-3099-IRES2-eGFP transfected 293FT 
cells (~213-fold) but not in the pCAG-IRES2-eGFP and 
mock controls (Figure 4). The observation indicated 
that the miR-3099 precursor transcript was successfully 
processed into mature functional miRNA in in vitro. 
The expression system was further validated in in utero 
by electroporating the pCAG-miR-3099-IRES2-eGFP 
into E15.5 ventricular zone. A mock control group 
was injected with fast green solution without any 
vector whereas a positive control group was injected 
with pCAG-IRES2-eGFP vector. Three days later, the 
electroporated germinal cells in the ventricular zone 
were expected to differentiate into either neurones or 
glial cells and migrated into the layer 2/3 of the mouse 
neocortex. Immunohistochemistry staining analysis 
showed eGFP positive cells migrated orderly into the 
layer 2/3 of the E18.5 neocortex in pCAG-IRES2-eGFP 
injected embryos but not in the mock control group, 
where no positive staining for eGFP cells were observed 
(Figure 5). Interestingly, pCAG-miR-3099-IRES2-eGFP 
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Figure 2: The generation and validation of pCAG-miR-3099-IRES2-eGFP 
(a) Vector maps for (i) pCAG-eGFP (ii) pCAG-IRES2-eGFP and (iii) pCAG-miR-3099-IRES2-eGFP. (b) The screening of clones by either PCR or 
double digestion with restriction enzyme approach followed by gel electrophoresis. Lane 1 is a 1kb DNA ladder. (i) The GFP with additional 
XhoI restriction site amplified from clones transformed with pCAG-eGFP-Xho1 (line 4 – 8) with the expected size of 1,045 bp. Lane 2 is a PCR 
amplicon generated from pCAG-eGFP original vector and lane 3 was digested eGFP PCR product. (ii) The IRES2 amplified from clones trans-
formed with pCAG-IRES2-eGFP (line 3 – 7) with the expected size of 964 bp. Lane 2 was digested IRES PCR product. (iii) EcoRI-HF and XmaI 
double digestion of clones transformed with pCAG-miR-3099-IRES2-eGFP yielding the miR-3099 insert of 366 bp in lane 3 but negative clones 
in the rest of the lanes. (c) The local alignment of sequences generated from the inserts of (i) pCAG-eGFP-XhoI, (ii) pCAG-IRES2-eGFP and (iii) 
pCAG-miR-3099-IRES2-eGFP positive clones with the reference sequences for each vector.
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Figure 3: Transfection of 293FT cells with constructed expression vectors
At 48 hours post-transfection, 293FT cells transfected with the mock reagent or negative control (a and d) do not express eGFP 
whereas GFP positive cells are observed in pCAG-IRES-eGFP (b and e) and pCAG-miR-3099-IRES2-eGFP (c and f) groups. 
injected group showed eGFP positive cells but disorderly 
migrated to all the different layers of the neocortex. 
The observations suggested that the expression system 
worked well in utero and the disarrayed migration effect 
of eGFP cells in pCAG-miR-3099-IRES2-eGFP injected 
group may be attributed to the overexpression effect of 
miR-3099 that warrant further investigation.
DISCUSSION
The functionality of pCAG-IRES2-eGFAP and pCAG-
miR-3099-IRES2-eGFP was validated via in vitro and 
in utero models. The CAG promoter was one of the 
most commonly used promoter to drive the expression 
of transgene even though it exhibits distinct preference 
cell to be transfected (3; 5). The promoter known 
as a constitutive promoter which can be used to 
promote expression in most tissue, however, in some 
of the cases the promoter can be silenced or promotes 
differential expression strength in selected type of cells 
(20–22).  The CAG promoter was shown to provide a 
long term expression of transgene particularly in stem 
cell differentiation as compared to CMV and β-actin 
promoter (23). Moreover, the CAG promoter can 
promote expression higher than EF1α in lung cells in 
mouse model (24). Based on their findings, the reporter 
activity driven by CAG promoter was maintained for 
up to 8 weeks and the expression was detectable 6 
Figure 4:  Validation of miR-3099 expression via stem-loop RT-qP-
CR. The expression level of miR-3099 is significantly upregulated in 
pCAG-miR-3099-IRES2-eGFP transfected 293FT cells as compared to 
pCAG-IRES2-eGFP transfected group. No differences are observed be-
tween the mock and pCAG-IRES2-eGFP groups. The mean ± SEM for 
each analysis is presented in the bar graphs. Asterisks denote the statis-
tical significant level at p<0.001 (***) based on the one-way ANOVA 
and post-hoc Bonferroni test. 
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Figure 5: Immunohistochemistry staining of eGFP expressing cells in the coronally sectioned E18.5 electroporated 
mouse brain. There is no observable eGFP positive cells in the mock or negative control neocortex (a and d). On 
the other hand, eGFP positive cells are seen on the pCAG-IRES2-eGFP (b and e) and pCAG-miR-3099-IRES2-eGFP 
(c and f) electroporated neocortices. The eGFP positive cells are expectedly organised at the layer 2/3 of the E18.5 
neocortex electroporated with pCAG-IRES2-eGFP but eGFP positive cells migrated randomly to all layers through-
out the neocortex electroporated with pCAG-miR-3099-IRES2-eGFP.
months after a single administration. In contrast, the 
gene expression driven by EF1α was lowly expressed 
and the expression was declined to the background 
level within a few weeks. However, the size of CAG 
promoter (~1.7 kb) was larger compared to CMV (~0.8 
kb) and EF1α (~1.2 kb) thus it increases the plasmid size 
and indirectly affecting the transfection efficiency (25). 
MiR-3099 expression was driven by CAG promoter and 
form pre-miRNA before transported into cytoplasm to 
form functional miRNA. To detect the expression of 
non-coding RNA, a reporter such as eGFP is desirable. 
When miR-3099 transgene and eGFP are expressed in 
a monocistronic manner, the endogenous processing of 
miR-3099 pre-miRNA will lead to defected transcript 
where eGFP will not be translated. The current design of 
the vector has a IRES2 site allowing translation of eGFP 
to happen despite the cleavage of miRNA precursor at 
upstream of eGFP. This bicistronic system allows the 
simultaneous processing of miR-3099 and expression of 
eGFP protein from the same RNA transcript. The IRES 
system, however, has been shown to cause a lower level 
of GFP expression (26).
We have constructed and validated a mammalian 
expression system to study our gene of interest, miR-
3099, in the developing mouse brain via in utero 
electroporation approach. The technique showed high 
efficiency in delivering the transgene with >80% of the 
injected embryos survived the development in vivo. 
Our analysis confirmed that miR-3099 was successfully 
processed into mature form and efficiently electroporated 
into the ventricular zone of the developing mouse brain. 
Electroporation process creates a transient electropores 
in the cell membrane using electrical pulses that 
subsequently allowing the negatively charge DNA or 
transgene of interest to be up taken into the cytoplasm 
(27). In addition, this method provides a simple way to 
express transgene in different subsets of progenitor cell 
in the cortex or at different time-points. This transient 
transfection might be lost in mitotic cell. However, 
in utero electroporation is an effective way to label 
neurones occupying different cortical lamina (28) and 
astrocytes (29). 
CONCLUSIONS
A new bicistronic mammalian expression system 
driven by CAG promoter with eGFP reporter gene was 
successfully constructed and validated for both in vitro 
and in utero electroporation into the mouse neocortex. 
Essentially, the expression system was functionally 
validated for in vitro and in utero expression of miR-
3099. The vector contains new multiple cloning sites 
that allow easy cloning of other protein-coding genes as 
well as non-coding RNAs. 
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